default author photo

Chris Argent

Scientia Clinical Research Ltd

SCHOLARLY PAPERS

1

DOWNLOADS

115

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

A Phase I, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Trial to Study the Safety and Immunogenicity of a DNA-Based Vaccine Against COVID-19 (COVIGEN) in Healthy SARS-CoV-2 Vaccine-Naïve Participants Aged 18 to 59 Years Old

Number of pages: 38 Posted: 21 Mar 2024
Children’s Hospital at Westmead - The National Centre for Immunisation Research and Surveillance (NCIRS), Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, The University of Western Australia, Scientia Clinical Research Ltd, University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney - Westmead Institute for Medical Research, The University of Sydney - Westmead Institute for Medical Research, The University of Sydney - Westmead Institute for Medical Research, The University of Sydney - NSW Health Pathology, The University of Sydney - Westmead Hospital, The University of Sydney - Sydney Infectious Diseases Institute, The University of Sydney - Westmead Hospital, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, Technovalia Pty. Ltd., Technovalia Pty. Ltd., BioNet-Asia Co Ltd and The University of Sydney - Westmead Institute for Medical Research
Downloads 115 (617,542)

Abstract:

Loading...

DNA, SARS-CoV-2, vaccine, neutralising antibody, COVID-19, safety, immunogenicity